Key result
Polypharmacy rises to ~26% among older US women despite stable overall prescription drug use.
Why the study?
Although statin therapy is indicated for women at elevated risk of CVD, safety concerns related to glucose elevations and myalgias may outweigh benefits for women at low absolute risk of CVD.
Cross-Sectional (n=18,686)
Answers are grounded in this paper and cite their sources.
Rising polypharmacy among midlife and older US women may heighten interaction risks; leaves open drivers and cardiovascular sequelae.
The 2013 American College of Cardiology/American Heart Association guidelines on the treatment of cholesterol recommend therapy for patients with (1) known cardiovascular disease (CVD); (2) low-density lipoprotein cholesterol (LDL-C) of 190 mg/dL or higher; (3) type 1 or type 2 diabetes mellitus and LDL-C between 70 mg/dL and 189 mg/dL (for ages 40-75); and 4) LDL-C between 70 mg/dL and 189 mg/dL and an estimated 10-year cardiovascular risk ≥7.5% (for ages 40-75), using their new risk calculator. Although statin therapy is indicated for women at elevated risk of CVD, safety concerns related to glucose elevations and myalgias may outweigh benefits for women at low absolute risk of CVD.
No takes yet. Share an insight, caveat, or question.
SHUFELT et al. (2014) conducted a cross-sectional in Prescription medication use and polypharmacy (n=18,686). Time period (1999-2020) vs. 1999-2000 survey cycle was evaluated on Any prescription medication use in the past 30 days (APC 0.1, 95% CI -0.2, 0.4).
Synapse has enriched 10 related papers. Consider them for comparative context: